Meeting
2022 ASCO Genitourinary Cancers Symposium
A genomic classifier for prostate cancer correlates with adverse pathologic features: Transcriptomic features of cribriform and intraductal carcinoma of the prostate.
Authors
Zaeem M Lone
Cleveland Clinic Lerner College of Medicine, Cleveland, OH
Zaeem M Lone , Tarik Benidir , Magdalena Rainey , Monica Nair , Elai Davicioni , Ewan Gibb , Sean Williamson , Jane Nguyen , Shilpa Gupta , Moshe Chaim Ornstein , Rahul D. Tendulkar , Christopher Weight , Eric A. Klein , Omar Y. Mian
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 268)
DOI
10.1200/JCO.2022.40.6_suppl.268
Abstract #
268
Poster Bd #
L12
Abstract Disclosures
Similar Posters
Poster
2014 Genitourinary Cancers Symposium
Transcriptome-wide analysis of matched biopsy and prostatectomy to measure genomic classifiers of prostate cancer progression and field effect.
First Author: Beatrice Knudsen
Poster
2024 ASCO Breakthrough
Analysis of heterochromatin remodeling as a mechanism of radiotherapy (RT) resistance through molecular profiling of radioresistant (RR) head and neck (HNC) and prostate cancers (PCa).
First Author: Evelyn Tan
Poster
2023 ASCO Annual Meeting
Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA).
First Author: Ashley Ross
Poster
2023 ASCO Annual Meeting
The genomic, transcriptomic, and immunologic landscape in solid tumors expressing leukocyte immunoglobulin-like receptor B2 (LILRB2).
First Author: Sandra Jones